Article
Gastroenterology & Hepatology
Barbara Olendzki, Vanni Bucci, Caitlin Cawley, Rene Maserati, Margaret McManus, Effie Olednzki, Camilla Madziar, David Chiang, Doyle Ward, Randall Pellish, Christine Foley, Shakti Bhattarai, Beth A. McCormick, Ana Maldonado-Contreras
Summary: This study aims to investigate the impact of specific foods on the intestinal microbiome in patients with IBD and explore the interactions between diet and immunity to provide personalized nutrition guidance for IBD patients with dysbiosis-related conditions.
Review
Cell Biology
Sheng Liu, Wenjing Zhao, Ping Lan, Xiangyu Mou
Summary: Inflammatory bowel disease (IBD) is a global disease with accelerating incidence worldwide, and dysbiosis of gut microbiota has been consistently associated with IBD. Some alterations in microbiome may have protective or causative effects on IBD. Therapeutic approaches targeting microbiome are a promising strategy for alleviating and curing IBD.
Article
Immunology
Sunil Kumar, Awanish Kumar
Summary: Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the gastrointestinal system that is increasing globally. The alteration in intestinal microbiota is associated with IBD, but the role of microbes in IBD is still controversial.
MICROBIAL PATHOGENESIS
(2022)
Review
Food Science & Technology
Qianqian Yao, Huiying Li, Linlin Fan, Yangdong Zhang, Shengguo Zhao, Nan Zheng, Jiaqi Wang
Summary: Inflammatory bowel disease (IBD) is a global public health issue caused by factors such as environmental factors, gut microbiota, the immune system, and host genetics. Dysbiosis in the gut microbiota can trigger abnormal immune responses and reduce tolerance to commensal bacteria. Further research into the complex interactions between food, gut microbiota, and immune response will contribute to the diagnosis, treatment, and management of IBD.
Article
Microbiology
Ram Hari Dahal, Shukho Kim, Yu Kyung Kim, Eun Soo Kim, Jungmin Kim
Summary: The gut microbiome consists of bacterial, archaeal, fungal, and viral communities. Various factors such as diet, age, stress, host genetics, and diseases can affect the diversity and abundance of bacterial species in the gut (dysbiosis). This study aimed to investigate the gut microbial composition in healthy controls (HCs) with Crohn's disease (CD), ulcerative colitis (UC), and ischemic colitis (IC) and identify biomarkers for distinguishing these conditions. The researchers used culture-independent and culture-based methods to analyze the gut microbial profile and validated biomarkers using quantitative Real-Time PCR (qPCR). They found that CD, UC, and IC conditions were associated with reduced bacterial diversity and species richness compared to HCs. Specific changes in microbial abundance were observed, including a decrease in Faecalibacterium prausnitzii and Prevotella sp. and an increase in potentially pathogenic bacteria such as Enterococcus faecium, Enterococcus faecalis, and Escherichia coli. Different bacteria were found to be abundant in CD, UC, and IC patients, suggesting potential biomarkers for each condition. Faecalibacterium prausnitzii reduction and increased abundance of specific bacteria could serve as biomarkers for CD, UC, and IC, respectively, aiding in diagnosis.
FRONTIERS IN MICROBIOLOGY
(2023)
Review
Microbiology
Shruti Ahlawat, Pramod Kumar, Hari Mohan, Sandeep Goyal, Krishna Kant Sharma
Summary: The human gut microbiota plays a crucial role in host health, with alterations in composition leading to the development of gastrointestinal disorders. Modulating gut microbiota composition and utilizing advanced treatment methods are key approaches for managing gut disorders in the future.
CRITICAL REVIEWS IN MICROBIOLOGY
(2021)
Review
Immunology
Samuel Adefisoye Lawal, Athalia Voisin, Hana Olof, Michael Bording-Jorgensen, Heather Armstrong
Summary: The gut microbiota plays a crucial role in the development of inflammatory bowel diseases, and there are significant differences in the microbiota communities of different intestinal sub-organs between healthy individuals and those with IBD. However, research focusing on the mycobiome and virome is limited, and the differences in microbiota composition in different segments of the intestinal tract in IBD remain largely unknown.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Gastroenterology & Hepatology
Mirae Lee, Eugene B. Chang
Summary: Inflammatory bowel diseases (IBD) result from the interaction of environmental, microbial, immunological, and genetic factors, with alterations in the gut microbiota playing a role in their development and progression. The use of microbiome-based therapies can potentially prevent, manage, and cure IBD, bridging the gap between basic sciences and clinical application through research findings.
Article
Microbiology
Anthea Pisani, Philipp Rausch, Corinna Bang, Sarah Ellul, Trevor Tabone, Claire Marantidis Cordina, Graziella Zahra, Andre Franke, Pierre Ellul
Summary: Dysbiosis in inflammatory bowel disease (IBD) has been identified as a potential cause or contributing factor to the development of the disease. Even after acute inflammation has subsided, significant differences and changes in community dynamics are observed in IBD patients. The gut microbiota is thought to play a crucial role in the development of IBD, and this study suggests that it is also a driver of chronicity in the disease, even in a state of remission.
MICROBIOLOGY SPECTRUM
(2022)
Article
Immunology
Maria Kulecka, Natalia Zeber-Lubecka, Aneta Balabas, Pawel Czarnowski, Katarzyna Baginska, Maria Glowienka, Anna Kluska, Magdalena Piatkowska, Michalina Dabrowska, Edyta Waker, Michal Mikula, Jerzy Ostrowski
Summary: In this study, the researchers compared the metagenomic and metabolomic profiles of Clostridioides difficile diarrheal cancer and inflammatory bowel disease patients. They found that C. difficile infection exacerbates intestinal dysbiosis.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2023)
Review
Medicine, General & Internal
HanZheng Zhao, WenHui Zhang, Die Cheng, LiuPing You, YueNan Huang, YanJie Lu
Summary: Inflammatory bowel disease (IBD) is a chronic non-specific inflammatory disease that occurs in the intestinal tract, with its pathogenesis related to factors such as environment, immune disorders, genetic susceptibility, and intestinal microbes. Dysbiosis of the gut microbiota plays an important role in the occurrence and development of IBD, but the causal relationship between dysbiosis and inflammation is not fully elucidated.
FRONTIERS IN MEDICINE
(2022)
Review
Microbiology
Jasminka Talapko, Aleksandar Vcev, Tomislav Mestrovic, Emina Pustijanac, Melita Jukic, Ivana Skrlec
Summary: The gut microbiota plays a crucial role in human health by participating in various physiological functions and acting as a metabolic organ. Changes in the composition of the intestinal microbiota have been linked to the pathogenesis of inflammatory bowel disease. The development of biological and immunomodulatory therapy has shown promising results in treating this condition, and lifestyle changes and novel approaches offer solutions for dysbiosis management.
Review
Immunology
Yusuke Yoshimatsu, Yohei Mikami, Takanori Kanai
Summary: The number of patients with inflammatory bowel disease is rapidly increasing in developed countries due to environmental changes causing dysbiosis. Bacteriotherapy, which corrects disturbed intestinal microbiota, is a promising treatment for this condition. Fecal microbiome transplantation in 2013 was a significant contribution to bacteriotherapy.
INFLAMMATION AND REGENERATION
(2021)
Review
Biochemistry & Molecular Biology
Carolina Battistini, Rafael Ballan, Marcos Edgar Herkenhoff, Susana Marta Isay Saad, Jun Sun
Summary: Inflammatory bowel disease is a chronic inflammation of the GI tract, including Crohn's disease and ulcerative colitis, associated with microbiota dysbiosis and vitamin D deficiency. Further studies are needed to explore the mechanisms and therapeutic potential related to vitamin D/VDR in gut microbiota modulation for IBD.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Nutrition & Dietetics
Liliana Lykowska-Szuber, Anna Maria Rychter, Magdalena Dudek, Alicja Ewa Ratajczak, Aleksandra Szymczak-Tomczak, Agnieszka Zawada, Piotr Eder, Maciej Lesiak, Agnieszka Dobrowolska, Iwona Krela-Kazmierczak
Summary: Studies have shown an increased risk of cardiovascular disease in patients with IBD, potentially due to inflammation-induced endothelial dysfunction and development of CVD, as well as gut microbiota dysbiosis. Dietary patterns have also been identified to influence the relationship between IBD and CVD.
Letter
Gastroenterology & Hepatology
Bridget M. Hron, Russell D. Cohen, Scott J. Johnson, Martha Skup, Jingdong Chao, Stacy A. Kahn
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2020)
Article
Gastroenterology & Hepatology
Colleen R. Kelly, Eugene F. Yen, Ari M. Grinspan, Stacy A. Kahn, Ashish Atreja, James D. Lewis, Thomas A. Moore, David T. Rubin, Alison M. Kim, Sonya Serra, Yanina Nersesova, Lydia Fredell, Dea Hunsicker, Daniel McDonald, Rob Knight, Jessica R. Allegretti, Joel Pekow, Imad Absah, Ronald Hsu, Jennifer Vincent, Sahil Khanna, Lyn Tangen, Carl Crawford, Mark C. Mattar, Lea Ann Chen, Monika Fischer, Razvan Arsenescu, Paul Feuerstadt, Jonathan Goldstein, David Kerman, Adam C. Ehrlich, Gary D. Wu, Loren Laine
Summary: This study demonstrated the high effectiveness and good safety profile of FMT for CDI. Assessment of new conditions at long-term follow-up will be important for determining the full safety profile of FMT as this registry grows.
Editorial Material
Gastroenterology & Hepatology
Rachel Rosen, Daniel Kamin, Tregony Simoneau, Kara Larson, Arda Hotz, Sangeeta Mauskar, Stacy A. Kahn
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
(2020)
Article
Pediatrics
Katherine F. Sweeny, Yanjia J. Zhang, Bonnie Crume, Colin A. Martz, Melissa M. Blessing, Stacy A. Kahn
Summary: The case describes a 16-year-old boy with MIS-C and severe inflammatory bowel disease. Treatment with a combination of steroids, intravenous immunoglobulin, and infliximab led to symptom resolution over a 3-week period. Emphasizing the need to investigate the impact of COVID-19 and MIS-C on inflammatory disorders.
Article
Gastroenterology & Hepatology
Maribeth R. Nicholson, Suchitra K. Hourigan, Maire Conrad, Alka Goyal, Kyle Jensen, Judith Kelsen, Melissa Kennedy, Madison Weatherly, Stacy A. Kahn
Summary: The impact of the 2019 US FDA safety alert and the COVID-19 pandemic on the use of FMT in children has led to changes in practices for many pediatric gastroenterologists, with a majority of programs being halted as a result.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Allergy
Janet Chou, Craig D. Platt, Saddiq Habiballah, Alan A. Nguyen, Megan Elkins, Sabrina Weeks, Zachary Peters, Megan Day-Lewis, Tanya Novak, Myriam Armant, Lucinda Williams, Shira Rockowitz, Piotr Sliz, David A. Williams, Adrienne G. Randolph, Raif S. Geha
Summary: MIS-C is a pediatric complication of severe acute respiratory syndrome coronavirus 2 infection characterized by multiorgan inflammation and cardiovascular dysfunction. Genetic risk factors such as variants in SOCS1, XIAP, and CYBB have been identified in patients with MIS-C, leading to an inflammatory immune cell transcriptome enriched in specific pathways even after recovery. This suggests a potential role for next-generation sequencing in identifying monogenic susceptibility to inflammation in previously healthy children with MIS-C.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2021)
Article
Gastroenterology & Hepatology
Suchitra K. Hourigan, Maribeth R. Nicholson, Stacy A. Kahn, Richard Kellermayer
Summary: FMT is currently the most effective treatment for rCDI, but regulatory challenges and concerns may delay approval for children, while biotherapeutics may replace FMT as the preferred option for adults.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
(2021)
Article
Medicine, General & Internal
Sahil Khanna, Aaron Tande, David T. Rubin, Alexander Khoruts, Stacy A. Kahn, Darrell S. Pardi
Summary: This study reported experience with FMT for rCDI during the COVID-19 pandemic and provided recommendations for managing rCDI and donor testing during this time. With appropriate donor screening, FMT can be performed safely for rCDI during the COVID-19 pandemic.
MAYO CLINIC PROCEEDINGS
(2021)
Article
Gastroenterology & Hepatology
Maribeth R. Nicholson, Erin Alexander, Sonia Ballal, Zev Davidovics, Michael Docktor, Michael Dole, Jonathan M. Gisser, Alka Goyal, Suchitra K. Hourigan, M. Kyle Jensen, Jess L. Kaplan, Richard Kellermayer, Judith R. Kelsen, Melissa A. Kennedy, Sahil Khanna, Elizabeth D. Knackstedt, Jennifer Lentine, Jeffery D. Lewis, Sonia Michail, Paul D. Mitchell, Maria Oliva-Hemker, Tiffany Patton, Karen Queliza, Sarah Sidhu, Aliza B. Solomon, David L. Suskind, Madison Weatherly, Steven Werlin, Edwin F. de Zoeten, Stacy A. Kahn
Summary: The efficacy of fecal microbiota transplantation (FMT) for recurrent Clostridioides difficile infection (rCDI) does not differ in children with inflammatory bowel disease (IBD). Key factors for a successful outcome include receiving FMT with fresh stool, absence of diarrhea prior to FMT, and a shorter time from rCDI diagnosis to FMT. Children with a failed FMT are more likely to have clinically active IBD and require hospitalization.
JOURNAL OF CROHNS & COLITIS
(2022)
Editorial Material
Gastroenterology & Hepatology
Maribeth R. Nicholson, Stacy A. Kahn
Summary: The study examines the perceptions of pediatric patients and parents regarding fecal microbiota transplantation for the treatment of ulcerative colitis.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
(2021)
Article
Pediatrics
Jacob M. Parnell, Maribeth R. Nicholson, Richard Kellermayer, Stacy A. Kahn
Summary: FMT is an important treatment option for pediatric patients with rCDI as it directly targets the underlying gut dysbiosis. This article will summarize the indications, procedures, effectiveness, and safety of FMT for rCDI in children.
Article
Education & Educational Research
Jill M. Plevinsky, Michele H. Maddux, Laurie N. Fishman, Stacy A. Kahn, Rachel N. Greenley
Summary: This study examines the relationship between the perceived impact of IBD on high school academics and college planning and college adjustment. The findings indicate that IBD greatly affects college planning, decision-making, and adjustment, potentially leading to difficulties in academic adjustment, attachment to the institution, and social adjustment during college.
JOURNAL OF AMERICAN COLLEGE HEALTH
(2022)
Article
Gastroenterology & Hepatology
Anthony Buisson, Wing Yan Mak, Michael J. Andersen, Donald Lei, Joel Pekow, Russell D. Cohen, Stacy A. Kahn, Bruno Pereira, David T. Rubin
Summary: This study aimed to compare the performance of using Fcal to detect endoscopic ulcerations in patients with pure ileal Crohn's disease and those with colonic or ileocolonic location. The results indicated that Fcal is highly effective in detecting endoscopic ulcerations regardless of the location of Crohn's disease, but a lower cutoff value is required in patients with pure ileal involvement.
INFLAMMATORY BOWEL DISEASES
(2021)
Correction
Gastroenterology & Hepatology
Sonia Michail, Maribeth Nicholson, Stacy A. Kahn, Richard Kellermayer
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
(2020)